2012-10-10 21:25:40 - New Pharmaceuticals market report from Global Markets Direct: "Hypotension - Pipeline Review, H2 2012"

Global Markets Direct's, 'Hypotension - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hypotension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypotension. Hypotension - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468467_hypotension_pipeline_review_h2_2012.a ..


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of

data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Hypotension.
* A review of the Hypotension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Hypotension pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Hypotension.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Hypotension pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypotension Overview
Therapeutics Development
An Overview of Pipeline Products for Hypotension
Hypotension Therapeutics under Development by Companies
Hypotension Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Hypotension Therapeutics - Products under Development by Companies
Hypotension Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Hypotension Therapeutics Development
Medinox, Inc.
Sangart, Inc.
Chelsea Therapeutics, Inc.
Ferring Pharmaceuticals, Inc.
Hypotension - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
selepressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
droxidopa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
droxidopa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOX-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hydrocortisone acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MP4-OX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atomoxetine + Acarbose + Pyridostigmine Bromide + Yohimbine + Midodrine + Modafinil + Octreotide + Diphenhydramine Hydrochloride + Ranitidine + Tranylcypromine + Ergotamine + Celecoxib + Pseudoephedrine + Methylphenidate + Indomethacin + Ibuprofen + Oxymetazoline + Acetazolamide + Rivastigmine tartrate + Carbidopa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Droxidopa + Alpha-Methyldopa + Carbidopa + Metyrosine + Levodopa + Atomoxetine + Metoclopramide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
metaraminol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
midodrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
droxidopa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
droxidopa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypotension Therapeutics - Drug Profile Updates
Hypotension Therapeutics - Discontinued Products
Hypotension Therapeutics - Dormant Products
Hypotension - Product Development Milestones
Featured News & Press Releases
Jun 21, 2012: Chelsea Therapeutics Announces Results From Two Phase III Studies Of Northera In Patients With Neurogenic OH
May 22, 2012: Chelsea Therapeutics Completes End-of-Review Meeting With FDA For Northera Capsules New Drug Application
Apr 27, 2012: Chelsea To Present Results From Pivotal Northera Study At AAN Annual Meeting
Mar 29, 2012: Shire Reports FDA's Update On Midodrine HCl
Mar 28, 2012: Chelsea Receives Complete Response Letter From FDA For Northera Capsules

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468467&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.